

RESEARCH

Open Access

The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma

Anna Djos¹, Tommy Martinsson¹, Per Kogner³ and Helena Carén^{1,2*}

Abstract

Background: Hypermethylation of promotor CpG islands is a common mechanism that inactivates tumor suppressor genes in cancer. Genes belonging to the *RASSF* gene family have frequently been reported as epigenetically silenced by promotor methylation in human cancers. Two members of this gene family, *RASSF1A* and *RASSF5A* have been reported as methylated in neuroblastoma. Data from our previously performed genome-wide DNA methylation array analysis indicated that other members of the *RASSF* gene family are targeted by DNA methylation in neuroblastoma.

Results: In the current study, we found that several of the *RASSF* family genes (*RASSF2*, *RASSF4*, *RASSF5*, *RASSF6*, *RASSF7*, and *RASSF10*) to various degrees were methylated in neuroblastoma cell lines and primary tumors. In addition, several of the *RASSF* family genes showed low or absent mRNA expression in neuroblastoma cell lines. *RASSF5* and *RASSF6* were to various degrees methylated in a large portion of neuroblastoma tumors and *RASSF7* was heavily methylated in most tumors. Further, CpG methylation sites in the CpG islands of some *RASSF* family members could be used to significantly discriminate between biological subgroups of neuroblastoma tumors. For example, *RASSF5* methylation highly correlated to *MYCN* amplification and INRG stage M. Furthermore, high methylation of *RASSF6* was correlated to unfavorable outcome, 1p deletion and *MYCN* amplification in our tumor material.

In conclusion: This study shows that several genes belonging to the *RASSF* gene family are methylated in neuroblastoma. The genes *RASSF5*, *RASSF6* and *RASSF7* stand out as the most promising candidate genes for further investigations in neuroblastoma.

Introduction

Neuroblastoma (NB) is the most commonly occurring solid extra-cranial tumor in children accounting for 6% of cancer incidence and 9% of cancer deaths in children [1]. It is a highly clinically and biologically heterogeneous cancer of the postganglionic sympathetic nervous system with tumors developing from immature or dedifferentiated neural crest cells [1,2]. Most tumors originate in the adrenal medulla or in paraspinal sympathetic ganglia. Common genetic alterations in NB tumors are

MYCN amplification, 17q gain, 1p deletion and loss of 11q [2,3]. The list of genes epigenetically silenced in cancer is growing and the inactivated genes represent all cellular pathways. Several genes have been reported as silenced by methylation in NB and one example is the Ras-associated family member *RASSF1A*, located at chromosome 3p [4]. CpG island methylation of *RASSF1A* has been reported as a frequent event in NB tumors and cell lines [4] and loss of heterozygosity (LOH) at 3p, i.e. the loci containing the *RASSF1A* gene, has been reported in primary NB tumors [5]. *RASSF1A* is also epigenetically silenced by promoter methylation in many other human tumors [6]. The Ras proto-oncogenes belong to a super-family of GTPases that participate in a range of cellular processes such as cell growth, adhesion, migration, differentiation and apoptosis [7], with defects in Ras signaling pathway resulting

* Correspondence: helena.caren@gu.se

¹Department of Clinical Genetics, Institute of Biomedicine, University of Gothenburg, Sahlgrenska University Hospital, SE-413 45, Gothenburg, Sweden

²Medical Genomics, UCL Cancer Institute, University College London, London, UK

Full list of author information is available at the end of the article

Table 1 Patient data

Tumor id	Outcome	INRG	age at diagnosis	age at follow up	1p-del	MNA	11q-del	17q-gain
10E6	NED	M	<18 m	>60 m	pos	pos	neg	pos
10E7	DOD	M	>18 m	<60 m	neg	neg	neg	pos
10R2	DOD	M	<18 m	<60 m	pos	pos	neg	pos
10R4	NED	MS	<18 m	>60 m	neg	neg	neg	neg
10R8	DOD	L	>18 m	<60 m	neg	neg	pos	neg
11E1	NED	M	>18 m	>60 m	neg	neg	pos	pos
11E8	NED	L	<18 m	>60 m	neg	neg	neg	neg
11R9	DOD	M	>18 m	<60 m	neg	neg	pos	pos
12E5	NED	MS	<18 m	>60 m	neg	neg	neg	neg
12R1	NED	M	<18 m	>60 m	pos	neg	neg	pos
12R6	DOD	M	>18 m	<60 m	pos	pos	neg	neg
12R9	NED	M	>18 m	>60 m	neg	pos	neg	neg
13R0	DOD	M	>18 m	<60 m	neg	pos	pos	pos?
13R1	DOD	L	>18 m	<60 m	neg	pos	pos	pos
15R8	NED	L	<18 m	>60 m	pos	neg	pos	pos
16E2	NED	L	<18 m	>60 m	neg	neg	neg	neg
16E9	DOD	M	>18 m	<60 m	neg	pos	neg	pos?
16R4	NED	L	>18 m	>60 m	neg	pos	neg	pos
17E2	NED	L	>18 m	>60 m	neg	neg	neg	neg
17E4	DOD	M	>18 m	<60 m	neg	pos	pos	pos
18E2	NED	L	>18 m	>60 m	pos	neg	neg	pos
18E4	DOD	M	<18 m	<60 m	neg	pos	pos	pos
18E5	NED	L	>18 m	>60 m	neg	neg	neg	neg
18E7	NED	L	>18 m	>60 m	neg	neg	neg	pos
18E8	NED	L	<18 m	>60 m	neg	neg	neg	neg
19R1	NED	L	>18 m	>60 m	neg	neg	neg	neg
19R6	DOD	L	<18 m	<60 m	neg	pos	pos	pos
20R8	NED	L	>18 m	>60 m	neg	pos	pos	pos
23R2	NED	L	>18 m	>60 m	neg	pos		
23R4	NED	L	<18 m	>60 m	neg	neg	neg	neg
25R6	DOD	M	>18 m	<60 m	neg	pos	pos	pos
25R7	NED	L	<18 m	>60 m	neg	neg	neg	neg
26R0	NED	M	>18 m	>60 m	pos	neg	pos	pos
26R1	NED	L	<18 m	>60 m	neg	neg	neg	neg
27R7	NED	L	<18 m	>60 m	neg	neg	neg	neg
28R2	NED		<18 m	>60 m	neg	pos	pos	pos
30R0	NED	M	>18 m	>60 m	pos	neg	neg	neg
32R2	NED	M	>18 m	>60 m	pos	neg	pos	pos
34R0	DOD	M	>18 m	<60 m	neg	neg	neg	pos
34R5	NED	L	<18 m	<60 m	neg	neg	neg	neg
35R5	NED	L	<18 m	<60 m	neg	neg	neg	neg
35R7	DOD	M	<18 m	<60 m	pos	neg	neg	neg
36R1	DOD	M	>18 m	<60 m	pos	neg	neg	pos
36R2	NED	M	>18 m	<60 m	pos	neg	neg	pos

Table 1 Patient data (Continued)

36R3	DOD	MS	<18 m	<60 m	neg	neg	neg	pos
37R5	NED	L	<18 m	<60 m	neg	neg	neg	neg
37R6	NED	L	<18 m	<60 m	neg	neg	neg	neg
38R6	NED	L	>18 m	<60 m	neg	neg	pos	neg
39R1	NED	M	>18 m	<60 m	neg	pos	pos	pos
3E2	DOD	M	>18 m	<60 m	pos	neg	neg	pos
43R2	DOD	M	<18 m	<60 m	neg	neg	neg	pos
43R3	NED	M	>18 m	<60 m	neg	pos	pos	pos
4E1	DOD	M	>18 m	<60 m	pos	neg	neg	pos
5E1	NED	L	<18 m	>60 m	neg	neg	neg	neg
6E9	DOD	L	>18 m	<60 m	pos	neg	pos	pos
8E4	NED	L	<18 m	>60 m	neg	neg	neg	neg
8E7	NED	L	>18 m	>60 m	neg	neg	neg	neg
9E5	DOD	M	>18 m	<60 m	neg	pos	pos	pos
9R9	DOD	M	>18 m	<60 m	pos	neg	pos	pos

NED, no evidence of disease; DOD, dead of disease; L, localized; M, metastatic; m, months.
 1p-del, 1p-deletion; MNA, MYCN amplification; 11q-del, 11q-deletion; neg, negative; pos, positive.

in disease and oncogenesis. The Ras proteins carry out their diverse functions via interaction with RASS effec-tors which have conserved Ras interacting domains. One of many such Ras interacting domains is the RA-domain, and the RA-domain is a common feature of the genes in the Ras-association domain family (RASSF). This family has ten members; *RASSF1-10*, which are divided into two groups, the classical members *RASSF1-6* and the N-terminal members *RASSF7-10* [8]. The classical *RASSF* family members have been reported to be involved in many biological processes such as microtubule stability, cell cycle control and apoptosis and are generally considered as tumor suppressors [8]. Based on our previous data using Illumina 27K methylation arrays [9] we noted that several of the *RASSF* genes were methylated in NB. Eight of the *RASSF* genes were included on the Illumina 27K methylation arrays (*RASSF1A*, *RASSF2*, *RASSF3*, *RASSF4*, *RASSF5*, *RASSF6*, *RASSF7* and *RASSF8*). The following seven *RASSF* genes were chosen for further methylation analysis; *RASSF2*, *RASSF4*, *RASSF5*, *RASSF6*, *RASSF7*, *RASSF8* and *RASSF10*). The two CpG sites in *RASSF3* were unmethylated in all NB tumors and this gene was therefore not investigated further. *RASSF8* however, we wanted to include in the verification analysis with BSP to see if surrounding CpG sites also were unmethylated since this gene has been reported as methylated in Childhood Leukemia cell lines [10]. *RASSF1A* was not analyzed further as this gene is well known to be deregulated in NB due to DNA methylation. Recent published data have shown that *RASSF10* is methylated in other cancers which led us to include this gene in our analyses. In addition to the *RASSF1A* gene,

DNA methylation was found in six out of seven analyzed *RASSF* genes (*RASSF2*, 4, 5–7 and 10). Several of the *RASSF* genes had reduced mRNA expression levels in NB cell lines and the methylation status of some of the *RASSF* genes was able to significantly discriminate between biological subgroups of NB tumors.

Material and methods

Cell lines and tumor material

A panel of nine NB cell lines; Kelly, NB69, SK-N-SH, SH-SY-5Y, SK-N-AS, SK-N-BE(2), SK-N-DZ, SK-N-FI and IMR-32 were used for analysis of DNA methylation status. All nine NB cell lines were subjected to epigenetic drug treatment and expression analysis with end-point RT-PCR or qRT-PCR. In addition, we have previously generated cDNA microarray data for SK-N-AS, SK-N-BE(2), SK-N-DZ and IMR-32 [9]. Data from Illumina Human Methylation27K DNA analysis BeadChips from fifty-nine primary NB tumors (Table 1) were also used, together with four NB cell lines, SK-N-AS, SK-N-BE(2), SK-N-DZ and IMR-32, one adrenal sample, unmethylated and methylated controls (EpiTect control DNA, Qiagen, Hilden, Germany) [9]. Control for the genomic content and the authenticity of all cell lines have been performed and genomic profiles of the cell lines generated [11]. Furthermore, short tandem repeat fingerprinting/genotyping of all the cell lines used were performed to verify the identity of cell lines, as described earlier [11].

Analysis of DNA methylation

1 µg of genomic DNA was bisulfite modified using the EpiTect kit (Qiagen) according to the manufacturer's

instructions. Methylation status of seven *RASSF* family genes was investigated using bisulfite sequencing, methylation-specific PCR (MSP) or combined bisulfite restriction analysis (COBRA).

Methylation-specific PCR (MSP) and bisulfite sequencing

PCR amplifications were performed according to Carén et al. [9]. Primers were designed with the Bisearch software [12] and are listed in Table 2. One fully methylated control sample, one unmethylated control sample and one 50/50 mixture of methylated and unmethylated control (EpiTect) were used to optimize the reaction conditions and to ensure that the bisulfite modified DNA

samples were equally amplified despite their methylation status. PCR products were visualized on a 2% agarose gel with GelRed (Biotinum, Hayward, CA). The methylation status of *RASSF2A* was determined using MSP and the methylation status of *RASSF5*, *RASSF7*, *RASSF8* and *RASSF10* were analyzed with bisulfite sequencing [9].

Combined bisulfite restriction analysis (COBRA)

The methylation status of *RASSF4* and *RASSF6* was determined using COBRA [16]. Bisulfite modified DNA was amplified as described above (primers in Table 2). For *RASSF4*, 2 µl of PCR product was incubated with 2U BstUI enzyme (CGCG) and 1xNEBuffer4 (New

Table 2 Primers used in this study

Gene	Method	Primer sequence	Product (bp)	AT °C	Primer design
<i>RASSF2A</i>	MSP	F: 5'-GTTTCGTCGTCGTTTTTAGGCG-3' R: 5'-AAAAACCAACGACCCCCGCG-3'	109	62	[13]
<i>RASSF2A</i>	MSP	F: 5'-AGTTTGTGTTGTTTTAGTG-3' R: 5'-AAAAACCAACAACCCCCACA-3'	109	60	[13]
<i>RASSF4</i>	COBRA	F: 5'-AGGATAYGATATATGTAGTGGTTTTGGATT-3' R: 5'-ATTATAACCCCTAAATTACTTAACAAAAATACAAA-3'	270	TD 65-55	[14]
<i>RASSF5A*</i>	BSP	F: 5'-TTAGGAAAGAGGAATATTTTAT-3' R: 5'-TAAACCTTCAACCCTACCTCTTC-3'	434	TD 60-50	[12]
<i>RASSF5C**</i>	BSP	F: 5'-GGGGTTTAGAGTTAGGGGTTTA-3' R: 5'-TATAACTTTATCCCTTACTA-3'	345	TD 60-50	[12]
<i>RASSF6</i>	COBRA	F: 5'-GTATAGGGAGTGGTTTAGGTTTTGATAT-3' R: 5'-ATCCCCATTTTTACCTATTATTCACACTATA-3'	353	TD 67-57	[10]
<i>RASSF7</i>	BSP	F: 5'-GAGAAAAGTTAGTTTTAGA-3' R: 5'-CTCAACAACCTTCTAATATAA-3'	592	TD 62-52	[12]
<i>RASSF8</i>	BSP	F: 5'-TTTTATAATGTAGYGTGGYGTGTTT-3' R: 5'-CRAAACTCRACRAAACTAAACRAAAACT-3'	374	TD 67-57	[10]
<i>RASSF10</i>	BSP	F: 5'-TTGTTTTGTTGTTTTYGYTTTTAGTAGATT-3' R: 5'-CRATTAACCTAACCAATTTACRAAAACCTTA-3'	634	TD 67-57	[10]
<i>RASSF2A</i>	qRT-PCR	F: 5'-AAGGGGTGGAGAGTGATATGAAGAG-3' R: 5'-AGGGACGTTTTGGTGGCTGTAGT-3'	194	60	[15]
<i>RASSF4</i>	qRT-PCR	F: 5'-GGACTGCGGATGACTGGAC-3' R: 5'-CCGACTTCTGAATGGACTTGCTGT-3'	126	56	[15]
<i>RASSF5</i>	End-point RT-PCR	F: 5'-CCTGGGCATGAACTGAGTGAAGA-3' R: 5'-tgatggcatctagggcaggtaga-3'	188	56	Manual
<i>RASSF6</i>	End-point RT-PCR	F: 5'-ATGGAGAGACTGAAGATGGC-3' R: 5'-CAGGGTGTGCTGTGATAAG-3'	203	56	[15]
<i>RASSF7</i>	End-point RT-PCR	F: 5'-CAGCAGAGCGAGCCTTGACAGGCTCA-3' R: 5'-CTGAGTGCAGGAGGGCCCTGTC-3'	149	59	Manual
<i>RASSF10</i>	qRT-PCR	F: 5'-CCATGACCCAGGAGAAACAG-3' R: 5'-TGCTGGCGAATTGTGTGGTC-3'	226	60	[10]

*cg17558126, **cg02589695.

MSP, Methylation specific PCR; BSP, Bisulfite sequencing PCR; COBRA, Combined bisulfite restriction PCR. qRT-PCR, Quantitative real time PCR; AT, Annealing temperature; TD, Touch down.

England BioLabs, Ipswich, MA) for 2 hours at 60°C. For *RASSF6*, 2 µl of PCR product was incubated with 1U of FastDigest TaqI (TCGA) and 1X FastDigest Green Buffer (Fermentas, Germany) for 15 minutes at 65°C. Digestion patterns were visualized on a 2% agarose gel with GelRed (Biotinum).

Epigenetic drug treatments and expression analysis

Changes in gene expression following treatment with the demethylating agent, 5-Aza-2'-deoxycytidine (5-Aza-dC; Sigma-Aldrich co, St Louis, MO) or/and the histone deacetylase inhibitor trichostatin A (TSA; Sigma-Aldrich) were analyzed with either end-point RT-PCR or qRT-PCR using Sybergreen (Applied Biosystems, Foster City, CA). RNA extraction and cDNA synthesis were done as previously described [9]. End-point RT-PCR was used for *RASSF5*, *RASSF6* and *RASSF7*. PCR reactions were denatured at 96°C for 10 minutes, followed by 35 cycles of 96°C for 30 seconds, annealing temperature (Table 2) for 30 seconds and 72°C for 30 seconds ending with a 7 minute extension step at 72°C. PCR products were taken at different time points (cycle 25, 30 and 35) to ensure the detection of the amplification product in the exponential phase. The housekeeping gene *GUSB* was included as an endogenous control. The end-point RT-PCR products were run on a 2% agarose gel and fragments were visualized with UV-light using GelRed (Biotinum). Quantitation of end-point RT-PCR was performed with ImageJ 1.45 software (NIH, Bethesda, MO) and normalization was done using *GUSB*. For the genes *RASSF2A*, *RASSF4* and *RASSF10*, expression analysis was performed with qRT-PCR using Sybergreen (Applied Biosystems) and the SDS software was used to extract Ct-values. Quantification was performed with the standard curve method [17]. *GUSB* was used for normalization.

Statistical analysis

The methylation beta-values from the CpG sites where methylation of the *RASSF* genes were detected were extracted from the 27K methylation arrays [9] and the difference in beta-values (methylation frequency) between different biological subgroups of NB were compared with Student's two-sided *t*-test. The tests included INRG stage, 5-year overall survival (5-OS), *MYCN* amplification status, 1p deletion, and 11q deletion. Correction for multiple testing was done with Bonferroni correction. The Illumina ID's of the CpG sites on the 27K methylation array are listed in Table 3.

Results

Methylation analysis with methylation array, bisulfite sequencing, MSP and COBRA

Bisulfite sequencing, MSP and COBRA assays were performed in order to verify that the methylated CpG sites

Table 3 Descriptives of the CpG sites from the 27K methylation array

Gene	ILMNID ^a	Relation to CGI	Methylation frequency (beta-value)	
			Mean	Range
<i>RASSF1</i>	cg00777121	CGI	0.69	0.13-0.95
	cg06063729	CGI	0.02	0-0.05
	cg06821120	CGI	0.12	0.02-0.64
	cg06980053	CGI	0.20	0.06-0.59
	cg08047457	CGI	0.75	0.05-0.99
	cg11035216	CGI	0.02	0-0.03
	cg15043975	CGI	0.06	0.04-0.11
<i>RASSF2</i>	cg21554552	CGI	0.61	0.04-0.96
	cg26357744	CGI	0.01	0-0.04
	cg16884569	CGI	0.01	0-0.03
	cg19614321	CGI shore	0.06	0.01-0.27
	cg07915282	CGI	0.02	0-0.07
	cg12157010	CGI	0.01	0-0.02
	cg13603099	CGI shore	0.01	0-0.02
<i>RASSF3</i>	cg17324128	CGI	0.10	0.04-0.24
	cg01860753	CGI	0.18	0.04-0.38
	cg02589695	CGI	0.23	0.06-0.51
	cg08617916	CGI	0.01	0-0.02
	cg10167296	CGI	0.04	0.02-0.1
	cg17558126	CGI	0.13	0.03-0.43
	cg19452316	CGI	0.04	0-0.08
<i>RASSF4</i>	cg22857604	CGI	0.04	0-0.1
	cg23520347	CGI	0.05	0.01-0.09
	cg24450312	CGI	0.09	0.02-0.16
	cg03996822	CGI shore	0.39	0-0.94
	cg08647446	CGI	0.12	0.05-0.54
	cg14896003	CGI shore	0.96	0.89-1.0
	cg07469792	CGI	0.01	0-0.03
<i>RASSF5</i>	cg22946876	CGI	0.00	0-0.03

ILMNID, Illumina ID; CGI, CpG island.

^ahttp://www.illumina.com/Documents/products/technotes/technote_cpg_loci_identification.pdf.

present on the 27K methylation array were indeed methylated and to explore if surrounding CpG sites had the same methylation status. Six of the seven *RASSF* genes were found to have methylated CpG islands in at least one NB cell line. Our 27K methylation array data showed dense *RASSF1A* methylation of NB primary tumors and cell lines which were expected since *RASSF1A* is well-known to be deregulated by DNA methylation in NB.

The *RASSF2A* MSP results confirmed the 27K methylation array data in that the cell line SK-N-AS showed

low level of methylation. *RASSF2A* DNA methylation was generally not found in primary NB tumors; only a few cases with low grade methylation were detected.

The *RASSF4* gene region that was analyzed with COBRA showed very low level of methylation in three cell lines; SK-N-AS, IMR-32 and Kelly. The 27K methylation array showed that *RASSF4* are generally not methylated in primary NB tumors even though some tumors had low level of methylation (methylation frequency below 25%).

Many of the primary NB tumors showed various levels of *RASSF5* methylation of at least one of the CpG sites present on the array, whereas some tumors were unmethylated at all sites present on the array (Table 3). SK-N-AS, IMR-32, SK-N-DZ and SK-N-BE(2) all showed partial methylation of *RASSF5* in at least one CpG site on the 27K methylation array. Two bisulfite sequencing assays were designed in order to confirm the *RASSF5* 27K methylation array results. One assay targeted the

CpG rich region upstream of the promoter where the longest *RASSF5* transcript (*RASSF5A*) is initiated. The other targeted a CpG rich region in the promoter where the medium-sized *RASSF5* transcript (*RASSF5C*) is initiated. Bisulfite sequencing showed that the CpG site cg17558126, located just upstream of *RASSF5A* was methylated in 7/9 NB cell lines and the site cg02589695, located in *RASSF5C* was methylated in 6/9 NB cell lines. For example the NB cell line NB69 was fully methylated whereas Kelly was partially methylated at the CpG sites in the *RASSF5A* fragment (Figure 1A). Bisulfite sequencing of *RASSF5* thus confirmed the 27K methylation array results for both CpG sites. In NB primary tumors, the methylation frequency (methylation beta-values) of two of the CpG sites on the 27K methylation array were significantly higher in INRG stage M compared to stage L (p-values <0.001, Bonferroni corrected <0.02 for all sites), (Figure 1B). The methylation beta-values were also for two of the sites significantly higher in *MYCN*-




Figure 1 *RASSF5* methylation and correlation to INRG stage and *MYCN* amplification. **(A)** Examples of bisulfite sequencing of *RASSF5* in the *RASSF5A* CpG island: top sequence NB69 and bottom sequence Kelly. CpG sites are underlined and C in the sequence indicates methylation and C/T in the sequence indicate partial methylation. **(B)** High methylation of *RASSF5* is significantly correlated to INRG stage M and *MYCN* amplification. P-values are indicated in the left upper corner in each graph. Box plot explanation; upper and lower hinges of the box represent the 75th percentile and 25th respectively; whiskers show highest and lowest values. Open circles represent outliers and asterisks show extremes.

amplified tumors compared to none-amplified (Bonferroni corrected p-values <0.02), (Figure 1B).

The 27K methylation array showed partial *RASSF6* methylation of at least one of the two CpG sites present on the array in all NB cell lines. The analyzed CpG island region of *RASSF6* was shown to be methylated in six out of nine (67%) cell lines according to our COBRA results (Figure 2A). The COBRA results thus confirmed partial methylation of *RASSF6* in IMR-32 and SK-N-BE(2) as well as the lower level of methylation in SK-N-AS. The methylation beta-values were significantly higher in patients with an unfavorable 5-year overall survival (Bonferroni corrected p-value <0.03), (Figure 2B). A higher methylation was also detected in 1p-deleted and *MYCN*-amplified tumors, with the most significant site located in the CpG island shore (Bonferroni corrected p-values of $<5 \times 10^{-7}$ and $p < 2 \times 10^{-4}$, respectively, Figure 2C).

The CpG site present on the 27K methylation array, located in the gene body of *RASSF7* was fully methylated in all four NB cell lines. Bisulfite sequencing of a fragment surrounding the transcriptional start site of *RASSF7* showed that eight of the nine (89%) NB cell lines were methylated, although to various levels (Figure 3). Bisulfite sequencing thus showed that the NB cell lines

were methylated also around the *RASSF7* transcription start site.

RASSF8 was unmethylated in all NB cell lines according to the 27K methylation array and bisulfite sequencing confirmed the array results. *RASSF8* was also unmethylated in the NB tumor material.

RASSF10 was unmethylated in eight of the nine (89%) cell lines whereas NB69 was partially methylated at all CpG sites. The methylation results are summarized in Figure 4A and the methylation frequencies of each CpG site on the 27K methylation array are listed in Table 3.

Expression analysis and up-regulation after 5-aza-dC and TSA treatment

RASSF2A mRNA expression in NB cell lines was very low overall, with no difference in expression between methylated and unmethylated cell lines (Figure 4B). Quantitative real-time PCR showed that *RASSF2A* expression was up-regulated in 4/9 NB cell lines after 5-Aza-dC/TSA treatment (Table 4).

RASSF4 expression was present in all NB cell lines with a lower expression in Kelly, SH-SY-5Y, SK-N-BE(2) and IMR-32 (Figure 4B). The lower expression in Kelly,




Figure 2 *RASSF6* methylation and correlation to outcome, 1p deletion and *MYCN* amplification. (A) Combined bisulfite restriction analysis of *RASSF6*. PCR products are cleaved with *TaqI*. Samples from left to right: Kelly, NB69, SK-N-SH, SH-SY-5Y, SK-N-AS, SK-N-BE(2), SK-N-DZ, SK-N-FI, IMR-32, methylated control (MQ), unmethylated control (UQ) and a 50% mixture of methylated and unmethylated control (MQ/UQ). (B) High methylation of *RASSF6* is correlated to an unfavorable outcome. (C) High methylation of *RASSF6* is highly correlated to 1p deletion and *MYCN* amplification.




Figure 3 Bisulfite sequencing of RASSF7. Top sequence NB69 and bottom sequence IMR-32. Cytosines/thymines in the CpG dinucleotide are underlined. C in the sequence indicates methylation, C/T indicates partial methylation and T indicates unmethylated CpG sites.

IMR-32 and SK-N-BE correlated with the presence of methylation according to either COBRA or 27K methylation array results. Further, the three cell lines (SK-N-AS, IMR-32 and SK-N-BE(2)), that showed low level of

methylation on the 27K methylation array were up-regulated following treatment with 5-Aza-dC and even more up-regulated following a combined treatment with 5-Aza-dC and TSA. The methylated cell line Kelly




Figure 4 Summary of RASSF gene expression and methylation. (A) Summary of RASSF gene methylation in NB cell lines. Methylation frequencies for each gene and NB cell line are indicated with a color code where fully methylated is marked with blue and unmethylated is marked with yellow. (B) Summary of RASSF gene expression in NB cell lines. mRNA expression levels for each gene and NB cell line are marked with a color code where blue indicate absent expression and yellow high expression level.

Table 4 Up-regulation of gene expression following treatment with 5-Aza-dC or 5-Aza-dC/TSA

		Rassf2A*	Rassf4*	Rassf5**	Rassf6**	Rassf7**	Rassf10*
Kelly	AZA				UD		
	AZA/TSA		↑		UD	↑	↑
NB69	AZA			↑	UD		
	AZA/TSA	↑		↑	UD		
SK-N-SH	AZA				UD		
	AZA/TSA				UD		
SH-SY-5Y	AZA			↑	UD	↑	
	AZA/TSA	↑		↑	UD		
SK-N-AS	AZA		↑	↑	UD		
	AZA/TSA		↑		UD		
SK-N-BE(2)	AZA		↑	↑	UD		
	AZA/TSA		↑	↑	UD	↑	
SK-N-DZ	AZA			↑		↑	↑
	AZA/TSA			↑		↑	
SK-N-FI	AZA		↑				
	AZA/TSA	↑	↑				
IMR-32	AZA		↑	↑	UD		
	AZA/TSA	↑	↑	↑	UD		

Arrows indicate a more than 2 fold up-regulation of gene expression following treatment. UD, undetermined - gene transcripts not detected in the PCR amplification. *qRT-PCR, **End-point RT-PCR.

also showed up-regulation of *RASSF4* following a combined treatment with 5-Aza-dC and TSA (Table 4).

RASSF5 expression varied between the cell lines and *RASSF5* mRNAs was up-regulated after epigenetic treatment in 6/9 of the NB cell lines (see Figure 4B, Figure 5 and Table 4). The highest level of up-regulation was seen in the cell lines IMR-32 and SH-SY-5Y.




Figure 5 Up-regulation of *RASSF5* expression following treatment with 5-Aza-dC and TSA. *RASSF5* end-point RT-PCR samples from left to right: Kelly A, B, C, NB69 A, B, C, SK-N-SH A, B, C, SH-SY-5Y A, B, C, SK-N-AS A, B, C, SK-N-BE(2) A, B, C, SK-N-DZ A, B, C, SK-N-FI A, B, C, IMR-32 A, B, C. Three positive controls (Pos. ctrl) and one non template control (NTC). A = untreated, B = AZA treated and C = AZA/TSA treated.

RASSF6 was not expressed in seven out of the nine (78%) NB cell lines and the remaining two had expression just above the detection limit. No up-regulation was seen following treatment with either 5-Aza-dC alone or in conjunction with TSA (Figure 4B and Table 4).

RASSF7 expression was overall very low in the NB cell lines with exception for SK-N-FI which had moderate expression (Figure 4B). *RASSF7* expression was strongly up-regulated in the methylated cell line SK-N-BE(2) after treatment with 5-Aza-dC in conjunction with TSA with both cDNA microarray and end-point RT-PCR. *RASSF7* was up-regulated in 4/9 NB cell lines following at least one of the treatments (Table 4).

Very low *RASSF10* expression was detected in five of the nine (56%) NB cell lines (Figure 4B). *RASSF10* expression was not up-regulated following epigenetic treatment in most of the NB cell lines (Table 4).

Discussion

In this study, we investigated whether the *RASSF* family genes are epigenetically silenced in NB. Data from our previously performed 27K methylation array showed that members of the *RASSF* gene family were methylated in NB cell lines and tumors [9]. The methylation status observed with the 27K methylation array was verified by DNA methylation analysis using bisulfite sequencing, MSP or COBRA, of the corresponding CpG island.

DNA methylation was most commonly observed in *RASSF7* (eight out of nine cell lines methylated), *RASSF5* (six to seven out of nine cell lines methylated depending on region analyzed) and *RASSF6* (six out of nine cell lines methylated) (Figure 4A). Gene expression analysis performed on NB cell lines showed in general low to moderate expression of the *RASSF* genes (Figure 4B). *RASSF4* had the highest expression in the NB cell lines whereas the mRNA levels of *RASSF6*, *RASSF7* and *RASSF10* were either below detection levels or very low in most NB cell lines. Also, the mRNA levels of *RASSF2A* and *RASSF5* were low in general. In order to see if *RASSF* gene expression could be restored, NB cell lines were treated with 5-Aza-dC/or TSA. Gene expression of most of the *RASSF* genes (*RASSF2A*, *RASSF4*, *RASSF5*, *RASSF7* and *RASSF10*) was up-regulated following epigenetic treatment, suggesting these genes may be epigenetically regulated. The concentration of each epigenetic drug and the treatment time will most

certainly affect the results of up-regulation. The chosen conditions of drugs and treatment times were based upon optimization conditions where re-expression of a panel of known methylated genes occurred [9]. More gene-specific optimizations of the epigenetic drug treatment conditions may be necessary in order to explore the re-activation potential fully. Also, up-regulation of a gene may be the result of their up-stream regulators being affected by treatment and it is also possible that other epigenetic mechanisms than DNA methylation are responsible for the up-regulation. Genes belonging to the *RASSF* family are generally considered as TSGs and many of the members have been reported as silenced by promoter methylation in human cancers, (Table 5).

RASSF1A is a TSG involved in a range of cellular processes that are essential for normal cell growth control. *Rassf1a* is one of the most commonly inactivated proteins in cancer and inactivation by promoter hypermethylation is a common event in various human

Table 5 Information of the *RASSF* genes studied in relation to tumorigenesis

Symbol	Chr	Product	Methylated in cancer	Comment
<i>RASSF1A</i>	3p21	Ras association domain family member 1	NB tumors and cell lines [4] as well as various human cancers, reviewed in [6]	TSG involved in regulation of cell proliferation. Promotes apoptosis and cell cycle arrest, involved in migration and maintenance of genomic stability (reviewed in [6]). KO of <i>RASSF1A</i> in mice enhances spontaneous tumor formation [18]; [19]
<i>RASSF2</i>	20p13	Ras association domain family member 2	Colorectal cancer [13], gastric cancer [20], nasopharyngeal carcinoma [21], breast-, lung and NSCLC tumors [22], thyroid cancer [23], pancreatic cancer [24]	Function as a TSG, reduces colony formation, promotes apoptosis and cell cycle arrest [25]; [15]; [21]; [22]; [23]
<i>RASSF4</i>	10q11	Ras association domain family member 4	Kidney-, breast- and lung cancer cell lines, breast- and lung primary tumors [14]	Have growth inhibitory properties and promotes apoptosis in lung- and breast tumor cell lines [14]
<i>RASSF5</i>	1q32	Ras association domain family member 5	NB cell lines [26]; [27], lung-, breast-, colorectal-, and kidney tumor cell lines and in primary NSCLC tumors [28], Wilms tumor [29], CCRCC [30], gastric cancer [20], colon cancer [13], squamous cell cancer of head and neck [31], hepatocellular carcinoma [32]	Also called NORE1 and forms heterodimers with <i>RASSF1A</i> [33]. Associate with microtubules and act growth inhibitory by a process involving p53. Promotes apoptosis when overexpressed or in the presence of activated Ras [34]. Neuroblastoma tumors, especially non <i>MYCN</i> -amplified, show suppressed <i>NORE1A</i> expression [27]
<i>RASSF6</i>	4q13	Ras association domain family member 6	Childhood leukemia [10]	Putative TSG in childhood leukemia [10]. Promotes apoptosis [35]. Downregulated at both mRNA and protein level in gastric cancer. Gastric cancer patients with <i>RASSF6</i> -negative tumors had worse outcome and higher recurrence rate than patients with <i>RASSF6</i> -positive tumors [36]
<i>RASSF7</i>	11p15	Ras association domain family (N-terminal) member 7		Centrosome associated protein necessary for spindle formation and completion of mitosis in the neural tube in <i>Xenopus</i> [8]. Required for completion of mitosis in human cells and KO results in mitotic arrest [37]
<i>RASSF8</i>	12p12	Ras association domain family (N-terminal) member 8	Childhood leukemia cell lines [10]	TSG candidate in lung cancer [38]. KO enhances anchorage independent growth in soft agar and promotes tumor formation in mice [39]
<i>RASSF10</i>	11p15	Ras association domain family (N-terminal) member 10	Childhood leukemia [10], thyroid cancer [40], primary glioblastomas and astrocytomas [41], malign melanoma [42]	Suggested as a regulator of mitosis. Over-expression decrease colony formation in soft agar [41]

Chr, chromosome; TSG, tumor suppressor gene; KO, knock out; NSCLC, non-small cell lung cancer; CCRCC, clear cell renal cell carcinoma; LOH, loss of heterozygosity.

malignancies, including NB [4]. Demonstrating the validity of our 27K methylation array data, we detected dense *RASSF1A* methylation of NB primary tumors and cell lines, which is in agreement with published data.

RASSF2A mRNA expression was in the current study generally low in NB cell lines and up-regulation of *RASSF2A* was seen following a combined treatment with 5-Aza-dC and TSA (4/9 NB cell lines) even though methylation at the *RASSF2A* CpG island was not commonly observed.

RASSF4 mRNA expression was detected in all NB cell lines and 5-Aza-dC and TSA treatment resulted in up-regulation of *RASSF4* mRNA levels in 5/9 NB cell lines. The strongest up-regulation was detected in the cell line IMR-32 which also showed the highest methylation level.

RASSF5, also called *NORE1* (Novel Ras Effector 1), is localized at 1q32.1 and has a 60% similarity to *RASSF1A*, the most commonly described methylated gene in cancer so far. The *RASSF5* gene encodes at least three different isoforms due to different promoter usage and alternative splicing. Two of the *RASSF5* isoforms, *RASSF5A* and *RASSF5C* are broadly expressed in most normal tissues. *RASSF5A* is the longest isoform transcribed from the most 5'-promoter and the isoform *RASSF5B* is produced by alternative splicing. The shorter isoform *RASSF5C* is transcribed from a more downstream promoter. Promoter methylation of *RASSF5A* has been reported to not occur in primary NB tumors and there are some conflicting data concerning methylation of NB cell lines, where NB cell lines have been described as low methylated or unmethylated in different studies [26,27]. Interestingly *RASSF5* was recently shown to be demethylated and up-regulated in the NB cell line SK-N-BE during ATRA-induced differentiation [43], suggesting that *RASSF5* could be aberrantly methylated in undifferentiated NB tumors cells but demethylated and re-expressed through differentiation. According to our 27K methylation array data, two CpG sites were methylated in NB primary tumors and cell lines. The methylated CpG sites were located in different *RASSF5* promoter CpG islands. The 27K methylation array site cg17558126 was located in the most 5'-promoter where transcription of *RASSF5A* starts and cg02589695 were located in a downstream promoter where the *RASSF5C* transcript starts. Bisulfite sequencing of the two regions revealed that both CpG sites present on the 27K methylation array were indeed methylated in most NB cell lines (Figure 4A). The methylation status of the CpG sites surrounding cg17558126 (*RASSF5A*) was highly variable throughout the CpG island, but most sites showed partial methylation, whereas the CpG sites surrounding cg02589695 (*RASSF5C*) were unmethylated in all NB cell lines. The variable methylation of CpG sites in this island might explain why there are conflicting published data regarding the methylation

status of *RASSF5A* in NB cell lines. Gene expression of *RASSF5A* have also been described as low in NB cell lines, with the highest expression in SK-N-SH and absent expression in IMR-32 [26], which is in agreement with our data (Figure 4A and 4B). *RASSF5* mRNA expression was in this study up-regulated for several NB cell lines. For example, the methylated cell line SH-SY-5Y was up-regulated after 5-Aza-dC treatment and even more up-regulated following a combined treatment with both 5-Aza-dC and TSA (Table 4). Two of the analyzed *RASSF5* CpG sites on the 27K methylation array were significantly more methylated in INRG stage M tumors compared to L tumors (Figure 1B). Also, *RASSF5A* methylation was highly correlated to *MYCN* amplification (Figure 1B). *RASSF5A* mRNA expression have also been reported as frequently down-regulated in NB and pheochromocytoma primary tumors and lower *RASSF5A* expression was seen in NB tumors without *MYCN*-amplification compared to *MYCN*-amplified tumors [27]. The methylation beta-value for two of the *RASSF5* sites was significantly higher in *MYCN*-amplified tumors compared to non-amplified tumors which contradicts an earlier report that showed lower expression of this gene in non-*MYCN*-amplified tumors [27].

RASSF6, located at chromosome region 4q13.3 has recently been suggested as a TSG candidate in childhood leukemia and was found to be silenced by heavy methylation across the whole CpG island in leukemia cell lines [10]. In the current study, *RASSF6* promoter methylation was found in 6/9 NB cell lines and *RASSF6* expression was absent or just above detection level in the panel of NB cell lines (Figure 4A and 4B). High methylation of *RASSF6* was significantly correlated to unfavorable outcome (5-OS), 1p deletion and *MYCN* amplification in our patient cohort (Figure 2B and 2C). Recently, *RASSF6* was shown to be down-regulated at both mRNA and protein level in gastric cancer tumors and loss of *RASSF6* expression correlated with poor survival and increased tumor recurrence rate [36]. Functional studies have indicated that *RASSF6* is involved in promoting apoptosis [35].

RASSF7, also known as *HRC1* (HRAS1 cluster 1), is located at chromosome region 11p15.5 and lacks the conserved SARAH domain present in *RASSF1-6*. To our knowledge, there are yet no reports of epigenetic silencing of *RASSF7* in cancer but important functions have been reported (Table 5). In this study, bisulfite sequencing showed methylation of the *RASSF7* promoter CpG sites in 8/9 NB cell lines (Figure 4A). All four NB cell lines present on the 27K methylation array were heavily methylated (84-96%) at the analyzed CpG site. Interestingly, the mRNA expression of *RASSF7* was very low or absent in most NB cell lines (Figure 4B). According to our cDNA microarray analysis the methylated NB cell

line SK-N-BE was strongly up-regulated following epigenetic treatment, which was verified with end-point RT-PCR (Table 4).

RASSF10, located at 11p15.2, has recently been reported as methylated and silenced in childhood leukemia [10], thyroid cancer [40] and in astrocytic glioma [41]. In this study the *RASSF10* mRNA expression was absent or just above the detection level in NB cell lines but low methylation was found in only 1/9 NB cell lines (Figure 4A and B).

Collectively, the *RASSF* family members have been demonstrated to have several tumor suppressive properties (Table 5). Although *RASSF* proteins lack catalytic activity, they are suggested to be non-enzymatic adaptors that are involved in growth and tumor suppression. The molecular mechanisms behind their growth suppressing properties are not yet elucidated but a number of reports show association with microtubules or centromeres indicating that the *RASSF* genes are important in microtubule dynamics and mitosis. In addition, the *RASSF* family genes participate in regulation of apoptosis and epigenetic silencing of *RASSF* genes may contribute to cancer by preventing RAS induced-apoptosis. In a normal cell, there is an important balance between signaling pathways that promote survival and those who promote apoptosis. If *RASSF* genes are silenced, the pro-apoptotic effects of RAS signaling may be lost which may favor the balance towards the pro-survival PI3 kinase pathway. Future studies regarding the exact function of the *RASSF* family genes and their interacting partners are essential to elucidate the role that epigenetic silencing of *RASSF* genes might play in NB and cancer in general.

Several genes from various cellular pathways have been reported as epigenetically silenced by DNA methylation in NB. For example, Caspase-8 (*CASP8*) located at 2q33 was one of the first genes to be reported as methylated in NB [44]. Aberrantly methylated genes could in the future be used in clinical patient stratification as biomarkers or as therapeutic targets. Our group and many others have shown that DNA methylation of single genes or a selected group of genes, are able to predict patient outcome, for a review see Decock et al., [45]. Epigenetic inactivation of *RASSF1A* has been reported as associated with high risk disease, age >1 year and poor survival for NB patients [46]. Further, *RASSF1A* hypermethylation in serum from patients with NB has been reported as a reliable prognostic predictor [47].

In summary, in addition to *RASSF1A* which is already known as frequently methylated in NB, this study highlights the *RASSF* gene family members *RASSF5*, *RASSF6* and *RASSF7* as promising candidates for further analysis in NB. These three genes are targeted by DNA methylation in NB primary tumors and cell lines and show low

levels of mRNA expression in NB cell lines. Also, CpG site specific DNA methylation of *RASSF5* and *RASSF6* was able to significantly discriminate between different subgroups of NB.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

AD carried out the experiments, analyzed the results and drafted the manuscript. HC planned and coordinated the study, performed experimental and statistical analysis and revised the manuscript. TM and PK provided clinical information. All authors read and approved the final manuscript.

Acknowledgements

This work has been supported by grants from the Swedish Cancer Society, the Children's Cancer Foundation, the Nilsson-Ehle Foundation, the Assar Gabrielsson Foundation and the Wilhelm and Martina Lundgren Research Foundation. We are grateful for help and access to instrumentation provided by the Sahlgrenska Academy Genomics Core Facility.

Author details

¹Department of Clinical Genetics, Institute of Biomedicine, University of Gothenburg, Sahlgrenska University Hospital, SE-413 45, Gothenburg, Sweden. ²Medical Genomics, UCL Cancer Institute, University College London, London, UK. ³Childhood Cancer Research Unit, Department of Woman and Child Health, Karolinska Institute, Karolinska Hospital, SE-17176, Stockholm, Sweden.

Received: 14 February 2012 Accepted: 30 May 2012

Published: 13 June 2012

References

1. Johnsen JI, Kogner P, Albiñ A, Henriksson MA: Embryonal neural tumours and cell death. *Apoptosis* 2009, **14**(4):424–438.
2. Brodeur GM: Neuroblastoma: biological insights into a clinical enigma. *Nat Rev Cancer* 2003, **3**(3):203–216.
3. Carén H, Kryh H, Nethander M, Sjöberg RM, Träger C, Nilsson S, Abrahamsson J, Kogner P, Martinsson T: High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. *Proc Natl Acad Sci U S A* 2010, **107**(9):4323–4328.
4. Astuti D, Agathangelou A, Honorio S, Dallol A, Martinsson T, Kogner P, Cummins C, Neumann HP, Voutilainen R, Dahia P, et al: *RASSF1A* promoter CpG island hypermethylation in pheochromocytomas and neuroblastoma tumours. *Oncogene* 2001, **20**(51):7573–7577.
5. Ejeskär K, Aburatani H, Abrahamsson J, Kogner P, Martinsson T: Loss of heterozygosity of 3p markers in neuroblastoma tumours implicate a tumour-suppressor locus distal to the FHIT gene. *Br J Cancer* 1998, **77**(11):1787–1791.
6. Donninger H, Vos MD, Clark GJ: The *RASSF1A* tumor suppressor. *J Cell Sci* 2007, **120**(Pt 18):3163–3172.
7. Cully M, Downward J: SnapShot: Ras Signaling. *Cell* 2008, **133**(7):1292–1292 e1291.
8. Sherwood V, Manbodi R, Sheppard C, Chalmers AD: *RASSF7* is a member of a new family of RAS association domain-containing proteins and is required for completing mitosis. *Mol Biol Cell* 2008, **19**(4):1772–1782.
9. Carén H, Djos A, Nethander M, Sjöberg RM, Kogner P, Enström C, Nilsson S, Martinsson T: Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma. *BMC Cancer* 2011, **11**(1):66.
10. Hesson LB, Dunwell TL, Cooper WN, Catchpoole D, Brini AT, Chiamaramonte R, Griffiths M, Chalmers AD, Maher ER, Latif F: The novel *RASSF6* and *RASSF10* candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. *Mol Cancer* 2009, **8**:42.
11. Kryh H, Carén H, Erichsen J, Sjöberg RM, Abrahamsson J, Kogner P, Martinsson T: Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors. *BMC Genomics* 2011, **12**:443.

12. Tusnady GE, Simon I, Varadi A, Aranyi T: **BiSearch: primer-design and search tool for PCR on bisulfite-treated genomes.** *Nucleic Acids Res* 2005, **33**(1):e9.
13. Hesson LB, Wilson R, Morton D, Adams C, Walker M, Maher ER, Latif F: **CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations.** *Oncogene* 2005, **24**(24):3987–3994.
14. Eckfeld K, Hesson L, Vos MD, Bieche I, Latif F, Clark GJ: **RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family.** *Cancer Res* 2004, **64**(23):8688–8693.
15. Akino K, Toyota M, Suzuki H, Mita H, Sasaki Y, Ohe-Toyota M, Issa JP, Hinoda Y, Imai K, Tokino T: **The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer.** *Gastroenterology* 2005, **129**(1):156–169.
16. Xiong Z, Laird PW: **COBRA: a sensitive and quantitative DNA methylation assay.** *Nucleic Acids Res* 1997, **25**(12):2532–2534.
17. Carén H, Fransson S, Ejskär K, Kogner P, Martinsson T: **Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours.** *Br J Cancer* 2007, **97**(10):1416–1424.
18. Tommasi S, Dammann R, Zhang Z, Wang Y, Liu L, Tsark WM, Wilczynski SP, Li J, You M, Pfeifer GP: **Tumor susceptibility of RASSF1a knockout mice.** *Cancer Res* 2005, **65**(1):92–98.
19. van der Weyden L, Tachibana KK, Gonzalez MA, Adams DJ, Ng BL, Petty R, Venkitaraman AR, Arends MJ, Bradley A: **The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis.** *Mol Cell Biol* 2005, **25**(18):8356–8367.
20. Endoh M, Tamura G, Honda T, Homma N, Terashima M, Nishizuka S, Motoyama T: **RASSF2, a potential tumour suppressor, is silenced by CpG island hypermethylation in gastric cancer.** *Br J Cancer* 2005, **93**(12):1395–1399.
21. Zhang Z, Sun D, Van do N, Tang A, Hu L, Huang G: **Inactivation of RASSF2A by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma.** *Int J Cancer* 2007, **120**(1):32–38.
22. Cooper WN, Dickinson RE, Dallol A, Grigorieva EV, Pavlova TV, Hesson LB, Bieche I, Broggin M, Maher ER, Zabarovsky ER, et al: **Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer.** *Oncogene* 2008, **27**(12):1805–1811.
23. Schagdarsurengin U, Richter AM, Hornung J, Lange C, Steinmann K, Dammann RH: **Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences.** *Mol Cancer* 2010, **9**:264.
24. Zhao L, Cui Q, Lu Z, Chen J: **Aberrant Methylation of RASSF2A in Human Pancreatic Ductal Adenocarcinoma and Its Relation to Clinicopathologic Features.** *Pancreas* 2012, **41**(2):206–211.
25. Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ: **RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor.** *J Biol Chem* 2003, **278**(30):28045–28051.
26. Lazcoz P, Munoz J, Nistal M, Pestana A, Encio I, Castresana JS: **Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma.** *BMC Cancer* 2006, **6**:254.
27. Geli J, Kogner P, Lanner F, Natalishvili N, Juhlin C, Kiss N, Clark GJ, Ekstrom TJ, Farnebo F, Larsson C: **Assessment of NORE1A as a putative tumor suppressor in human neuroblastoma.** *Int J Cancer* 2008, **123**(2):389–394.
28. Hesson L, Dallol A, Minna JD, Maher ER, Latif F: **NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers.** *Oncogene* 2003, **22**(6):947–954.
29. Morris MR, Hesson LB, Wagner KJ, Morgan NV, Astuti D, Lees RD, Cooper WN, Lee J, Gentle D, Macdonald F, et al: **Multigene methylation analysis of Wilms' tumour and adult renal carcinoma.** *Oncogene* 2003, **22**(43):6794–6801.
30. Chen J, Lui WO, Vos MD, Clark GJ, Takahashi M, Schoumans J, Khoo SK, Petillo D, Lavery T, Sugimura J, et al: **The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas.** *Cancer Cell* 2003, **4**(5):405–413.
31. Steinmann K, Sandner A, Schagdarsurengin U, Dammann RH: **Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma.** *Oncol Rep* 2009, **22**(6):1519–1526.
32. Macheiner D, Gauglhofer C, Rodgarkia-Dara C, Grusch M, Brachner A, Bichler C, Kandioler D, Sutterluty H, Mikulits W, Schulte-Hermann R, et al: **NORE1B is a putative tumor suppressor in hepatocarcinogenesis and may act via RASSF1A.** *Cancer Res* 2009, **69**(1):235–242.
33. Ortiz-Vega S, Khokhlatchev A, Nedwidek M, Zhang XF, Dammann R, Pfeifer GP, Avruch J: **The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1.** *Oncogene* 2002, **21**(9):1381–1390.
34. Calvisi DF, Donniger H, Vos MD, Birrer MJ, Gordon L, Leaner V, Clark GJ: **NORE1A tumor suppressor candidate modulates p21CIP1 via p53.** *Cancer Res* 2009, **69**(11):4629–4637.
35. Ikeda M, Hirabayashi S, Fujiwara N, Mori H, Kawata A, Iida J, Bao Y, Sato Y, Iida T, Sugimura H, et al: **Ras-association domain family protein 6 induces apoptosis via both caspase-dependent and caspase-independent pathways.** *Exp Cell Res* 2007, **313**(7):1484–1495.
36. Wen Y, Wang Q, Zhou C, Yan D, Qiu G, Yang C, Tang H, Peng Z: **Decreased Expression of RASSF6 Is a Novel Independent Prognostic Marker of a Worse Outcome in Gastric Cancer Patients after Curative Surgery.** *Ann Surg Oncol* 2011 Dec, **18**(13):3858–67.
37. Recino A, Sherwood V, Flaxman A, Cooper WN, Latif F, Ward A, Chalmers AD: **Human RASSF7 regulates the microtubule cytoskeleton and is required for spindle formation, Aurora B activation and chromosomal congression during mitosis.** *Biochem J* 2010, **430**(2):207–213.
38. Falvella FS, Manenti G, Spinola M, Pignatiello C, Conti B, Pastorino U, Dragani TA: **Identification of RASSF8 as a candidate lung tumor suppressor gene.** *Oncogene* 2006, **25**(28):3934–3938.
39. Lock FE, Underhill-Day N, Dunwell T, Matallanas D, Cooper W, Hesson L, Recino A, Ward A, Pavlova T, Zabarovsky E, et al: **The RASSF8 candidate tumor suppressor inhibits cell growth and regulates the Wnt and NF-kappaB signaling pathways.** *Oncogene* 2010, **29**(30):4307–4316.
40. Schagdarsurengin U, Richter AM, Wohler C, Dammann RH: **Frequent epigenetic inactivation of RASSF10 in thyroid cancer.** *Epigenetics* 2009, **4**(8):571–576.
41. Hill VK, Underhill-Day N, Krex D, Robel K, Sangan CB, Summersgill HR, Morris M, Gentle D, Chalmers AD, Maher ER, et al: **Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis.** *Oncogene* 2011, **30**(8):978–989.
42. Helmbold P, Richter AM, Walesch S, Skorokhod A, Marsch WC, Enk A, Dammann RH: **RASSF10 Promoter Hypermethylation Is Frequent in Malignant Melanoma of the Skin but Uncommon in Nevus Cell Nevi.** *J Invest Dermatol* 2012 Mar, **132**(3 Pt 1):687–94.
43. Das S, Foley N, Bryan K, Watters KM, Bray I, Murphy DM, Buckley PG, Stallings RL: **MicroRNA mediates DNA methylation events triggered by retinoic acid during neuroblastoma cell differentiation.** *Cancer Res* 2010, **70**(20):7874–7881.
44. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ: **Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN.** *Nat Med* 2000, **6**(5):529–535.
45. Decock A, Ongenaert M, Vandesompele J, Speleman F: **Neuroblastoma epigenetics: from candidate gene approaches to genome-wide screenings.** *Epigenetics* 2011, **6**(8):962–970.
46. Yang Q, Zage P, Kagan D, Tian Y, Seshadri R, Salwen HR, Liu S, Chlenski A, Cohn SL: **Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.** *Clin Cancer Res* 2004, **10**(24):8493–8500.
47. Misawa A, Tanaka S, Yagyu S, Tsuchiya K, Iehara T, Sugimoto T, Hosoi H: **RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker.** *Br J Cancer* 2009, **100**(2):399–404.

doi:10.1186/1476-4598-11-40

Cite this article as: Djios et al.: The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma. *Molecular Cancer* 2012 **11**:40.